All In Biotech

Drug Trial Radar · NCT04358731

Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age

A Phase 2/3, Randomized, Observer-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine (NmCV-5) and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age

Last checked: Nov 20, 2026Latest source record: Sep 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,640 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,640

Actual

Start

Dec 27, 2019

Primary completion

Mar 24, 2021

Study completion Mar 24, 2021

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 2/3, randomized, observer blind, multi-centre, controlled study to evaluate the safety, immune response and consistency of immune response of three consecutively manufactured lots of NmCV-5 in healthy individuals between the ages of 18 to 85 years (both inclusive). The immune response of NmCV-5 will also be statistically compared against a licensed conjugate vaccine against ACYW (Menactra). A total of 1640 subjects 18 to 85 years of age will be accrued contemporaneously across three age groups - 18 to 29 years, 30 to 60 years, and 61 to 85 years. Within each age group subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra. The NmCV-5 subjects in 18-29 year age group will be further randomized 1:1:1 into three different lots (Lot A, B \& C) of NmCV-5. All the randomized subjects will receive a single dose of 0.5 ml of NmCV-5 or Menactra on Day 1. Post vaccination site visits are planned on Days 8, 29 and 180 and a telephonic call at Day 85.

Conditions

  • Vaccine for Meningococcal Disease

Interventions

  • NmCV-5Biological

    The NmCV-5 is a fixed-combination available as the lyophilized powder containing meningococcal groups A and X polysaccharides conjugated to tetanus toxoid and meningococcal groups C, W and Y polysaccharides conjugated to CRM197 protein. The vaccine will be reconstituted with normal saline just prior to administration. The NmCV-5 lyophilized powder component contains sucrose, sodium citrate and trometamol as excipients. This component is presented as a freeze-dried powder in a single dose vial. No preservative or adjuvant is present in the vaccine. The normal saline diluent is a sterile clear colorless liquid in a single dose glass ampoule.

  • MenactraBiological

    The control vaccine is the licensed meningococcal serogroups ACYW conjugate vaccine (Menactra), manufactured by Sanofi Pasteur Incorporated. Menactra is supplied as a single 0.5 mL dose formulated in sodium phosphate buffered isotonic sodium chloride solution to contain 4 mcg each of meningococcal A, C, Y, and W polysaccharides conjugated to approximately 48 mcg of diphtheria toxoid protein carrier. No preservative or adjuvant is added during manufacture.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. rSBA assay Geometric Mean Titers (GMTs) at Day 29 against serogroups A, C, W, Y and X in subjects 18 to 29 years of age.Time frame: 1 month after vaccination
  2. Percentage of subjects with seroresponse 28 days after vaccination in pooled NmCV-5 and Menactra vaccine groupsTime frame: 28 days after immunization

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Post Graduate Institute of Medical Education and Research (PGIMER)

    Chandigarh, India

  • Kempegowda Institute of Medical Sciences (KIMS) Hospital & Research Centre, K. R. Road, V. V. Puram, Bangalore 560004, Karnataka, India

    Bangalore, Karnataka, India

  • M S Ramaiah Medical College and Hospitals, Bangalore

    Bangalore, Karnataka, India

  • T. N. Medical College and B. Y. L. Nair Charitable

    Mumbai, Maharashtra, India

  • Seth G S Medical College & KEM Hospital

    Mumbai, Maharashtra, India

  • Jahangir Clinical Development Centre Pvt. Ltd., Pune

    Pune, Maharashtra, India

  • KEM Hospital Research Centre, Vadu Rural Health Program, Vadu Budruk, Taluka - Shirur, District - Pune 412216 , Maharashtra Pune

    Pune, Maharashtra, India

  • Department of community Medicine, Dr Sushila Nayar School of Public Health, Mahatma Gandhi Institute of Medical Sciences, Sewagram

    Wardha, Maharashtra, India

  • Hamdard Institute of Medical Sciences and Research (HIMSR), and Associated Hakeen Abdul Hameed Centenary Hospital (HAHCH) Jamia Hamdard, Hamdard Nagar, New Delhi - 110062

    New Delhi, National Capital Territory of Delhi, India

  • Institute of Medical Sciences and SUM Hospital Bhubaneshwar

    Bhubaneswar, Odisha, India

  • Sri Ramachandra Institute of Higher Education and Research

    Chennai, Tamil Nadu, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.